Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06164587 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Michelle Abou-Jaoude.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
9
Study locations

NCT06164587: Active Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by Michelle Abou-Jaoude.

NCT06164587 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is active but no longer recruiting, run by Michelle Abou-Jaoude. The registered enrollment target is 30 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06164587, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is active but no longer recruiting, sponsored by Michelle Abou-Jaoude.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
9
Study locations

Study Summary

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30. Participants will have 7 scheduled visits - Screening with baseline (injection), safety visit 2 days after injection, week 4, week 13 (injection), safety visit 2 days after injection, week 17, week 26. Exams will look for continuous changes in visual acuity, change in area of geographic atrophy lesions in diagnostic imaging, response measured by multifocal electroretinogram, change in reading speed, and change in microperimetry response.

Primary Outcome

Frequency of participants experiencing ocular or systemic adverse events.

Conditions Studied

Age-related Macular Degeneration Geographic Atrophy

Interventions

  • DRUG K8

Study Locations (9)

Virginia

  • Southeastern Retina Associates - Bristol
  • Vistar Eye Center - Roanoke

California

  • Loma Linda University - Loma Linda

Kentucky

  • University of Kentucky Advanced Eye Care - Lexington

Maine

  • The Maine Eye Center - Portland

Oregon

  • Oregon Eye Consultants, Cascade Medical Research - Eugene

South Carolina

  • Hilton Head Retina Institute - Hilton Head

South Dakota

  • Ophthalmology LTD - Sioux Falls

Tennessee

  • Southeastern Retina Associates - Hixson

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-04-18
Est. Completion 2026-06
Phase Phase 1
Michelle Abou-Jaoude

3 total trials

What the registry record for NCT06164587 still lists

NCT06164587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which K8 is the first listed.

NCT06164587 lists 9 locations in 8 states (Virginia, California, Kentucky).

Frequently Asked Questions

What is clinical trial NCT06164587 about?

NCT06164587 is a clinical study titled "Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy". This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be admini...

What is the current status of trial NCT06164587?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-04-18. Estimated completion is 2026-06.

What conditions does trial NCT06164587 study?

This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.

What interventions are being tested in trial NCT06164587?

The interventions under investigation include: K8 (DRUG).

Who is sponsoring clinical trial NCT06164587?

This trial is sponsored by Michelle Abou-Jaoude, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06164587 being conducted?

This trial has 9 study locations across California, Kentucky, Maine, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06164587's enrollment target sits among peer trials

30 59th of 74 higher than 15 of 74 other Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06164587, the US trial registry maintained by the National Library of Medicine. NCT06164587 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.